Biotech · Private company
Faes Farma, S.A.
Track this companyFree. Adds Faes Farma, S.A. to your Dealase workspace and tells you when its record changes.
Clinical trials30 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- Bilastine Ophthalmic Solution 0.6%Phase 3 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
- Ketotifen Ophthalmic Solution 0.025% (Zaditen)Phase 3 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
- Vehicle of Bilastine Ophthalmic SolutionPhase 3 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
- BilastinePhase 2 · Seasonal Allergic RhinitisClinicalTrials.gov · fetched Nov 12, 2026
- Bilastine 0.2%Phase 2 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
- Bilastine 0.4%Phase 2 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
- Bilastine 0.6%Phase 2 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
- Bilastine 0%Phase 2 · Allergic ConjunctivitisClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials3
- A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model.PHASE3 · COMPLETED · started Apr 7, 2018ClinicalTrials.gov NCT03479307 · fetched Nov 12, 2026
- A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® ModelPHASE2 · COMPLETED · started Jul 20, 2017ClinicalTrials.gov NCT03231969 · fetched Nov 12, 2026
- Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SARPHASE2 · COMPLETED · started Dec 1, 2007ClinicalTrials.gov NCT00574379 · fetched Nov 12, 2026